F-group (family)
191.1.1.41 EthR_C
Ligands and drugs
113
Member domains
97
with ligand contacts (≤ 4 Å)
85.8% of members
96
with DrugDomain annotations
85.0% of members
25
with a DrugBank compound
22.1% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 191.1.1.41 belongs to X-group 191 Tetracyclin repressor-like, C-terminal domain, which binds 10.0 ligand superclasses per 20 proteins, broader than 93% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB02425 | CNS | Hexadecyl Octanoate | 3 |
| DB11905 | 9EN | Sutezolid | 3 |
| DB00601 | ZLD | Linezolid | 1 |
| DB08469 | RF1 | tert-butyl 4-(3-thiophen-2-yl-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate | 1 |
| DB08470 | RF2 | 3-(4-fluorophenyl)-5-phenyl-4H-1,2,4-triazole | 1 |
| DB08471 | RF3 | 1-(thiophen-2-ylacetyl)-4-(3-thiophen-2-yl-1,2,4-oxadiazol-5-yl)piperidine | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| 9EN | ~{N}-[[(5~{S})-3-(3-fluoranyl-4-thiomorpholin-4-yl-phenyl)-2-oxidanylidene-1,3-oxazolidin-5-yl]methyl]ethanamide | 3 |
| CNS | HEXADECYL OCTANOATE | 3 |
| 8YH | ~{N}-butyl-4-methyl-piperidine-1-carboxamide | 2 |
| HYV | [4-(phenylmethyl)piperidin-1-yl]-[1-(5-pyrrol-1-yl-1,3,4-thiadiazol-2-yl)piperidin-4-yl]methanone | 2 |
| LL4 | 4-methyl-1-{4-[3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}pentan-1-one | 2 |
| 2B2 | 4-(2-methyl-1,3-thiazol-4-yl)-N-(3,3,3-trifluoropropyl)benzamide | 1 |
| 2B3 | 4-(2-{[(propylsulfonyl)amino]methyl}-1,3-thiazol-4-yl)-N-(3,3,3-trifluoropropyl)benzamide | 1 |
| 2D1 | N-(3-methylbutyl)-4-(2-methyl-1,3-thiazol-4-yl)benzenesulfonamide | 1 |
| 2G1 | 4-(2-methyl-1,3-thiazol-4-yl)-N-(3,3,3-trifluoropropyl)benzenesulfonamide | 1 |
| 2H2 | 4-{3-[(phenylsulfonyl)amino]prop-1-yn-1-yl}-N-(3,3,3-trifluoropropyl)benzamide | 1 |
| 3SE | 4,4,4-trifluoro-1-{4-[3-(1,3-thiazol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}butan-1-one | 1 |
| 3SF | 5,5,5-trifluoro-1-{4-[3-(1,3-thiazol-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}pentan-1-one | 1 |
| 5T0 | 3-[1-[4-(methylaminomethyl)phenyl]piperidin-4-yl]-1-pyrrolidin-1-yl-propan-1-one | 1 |
| 5T4 | ~{N}-[(1-pyrimidin-2-ylpiperidin-4-yl)methyl]pyrrolidine-1-carboxamide | 1 |
| 5TB | 3-cyclopentyl-1-[3-[4-(methylaminomethyl)phenyl]-1,3-diazinan-1-yl]propan-1-one | 1 |
| 5TC | 3-[1-(4-cyanophenyl)piperidin-4-yl]-~{N}-[(4-piperidin-1-ylphenyl)methyl]propanamide | 1 |
| 5TD | 4-[4-(3-oxidanylidene-3-pyrrolidin-1-yl-propyl)piperidin-1-yl]benzenecarbonitrile | 1 |
| 5TE | 3-cyclopentyl-~{N}-(3-piperidin-1-ylphenyl)propanamide | 1 |
| 5TG | ~{tert}-butyl ~{N}-methyl-~{N}-[[4-[4-(3-oxidanylidene-3-pyrrolidin-1-yl-propyl)piperidin-1-yl]phenyl]methyl]carbamate | 1 |
| 5TO | 3-cyclopentyl-1-pyrrolidin-1-yl-propan-1-one | 1 |